Recruiting

Trial purpose

This is a phase 3, randomized, placebo-controlled study of the efficacy and safety of enlicitide decanoate, an oral proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor, in participants with high cardiovascular risk. The primary objective is to evaluate the efficacy of enlicitide decanoate compared with placebo in increasing the time to the first occurrence of major adverse cardiovascular events (MACE) including coronary heart disease (CHD) death, ischemic stroke, myocardial infarction (MI), acute limb ischemia or major amputation, or urgent arterial revascularisation.

View full trial information on Clinicaltrials.gov
NATIONAL TRIAL REFERENCE NUMBER NCT06008756
Conditions Arteriosclerosis, Hypercholesterolemia
Age Range 18+
Sex All
Current trial phase 1
Trial start and end dates [10-09-2023] [11-29-2029]

About the trial

Eligibility

Only a qualified healthcare professional can determine if you are eligible to take part in a clinical trial. However, this information may be useful in starting a conversation with your doctor.

Conditions

Arteriosclerosis, Hypercholesterolemia

View full trial eligibility

Trial Phase 3

Length of study: The CORALreef Outcomes study lasts on average 4.5 years, up to 6 years.

Trial locations (9)

Locations shown may have changed in some cases. Please call the number listed in the location results to confirm the nearest trial site. Talk with a trial site member for more information.

What can you do next?

Discuss with your doctor or care team

Print this page with details about the trial or email it to your doctor to discuss the clinical trial during your next visit.

Get help talking with your doctor or care team

NATIONAL TRIAL REFERENCE NUMBER

NCT06008756

When you talk with your doctor or clinical trial team member, please have the national trial reference number available.

This site is registered on wpml.org as a development site. Switch to a production site key to remove this banner.